Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKM Injection + R-CHOP in DLBCL
NCT00846157Phase 3Unknown
- Sponsor
- Nankai Biotech
- Start
- Sep 2007
- Primary completion
- Sep 2011
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 3 trial of NKM injection in diffuse large B-cell lymphoma (DLBCL), sponsored by Nankai Biotech. Status: unknown.
02
Drugs
NKM injection
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00846157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846157.